Materials Today Bio, Год журнала: 2024, Номер 25, С. 100965 - 100965
Опубликована: Янв. 21, 2024
Язык: Английский
Frontiers in Bioengineering and Biotechnology, Год журнала: 2023, Номер 11
Опубликована: Фев. 2, 2023
Applying reactive polymer materials sensitive to biological stimuli has recently attracted extensive research interest. The special physiological effects of oxygen species (ROS) on tumors or inflammation and the application ROS-responsive polymers as drug-delivery systems in organisms have much attention. ROS is a vital disease signal molecule, unique accumulation pathological sites may enable deliver payload (such drugs, prodrugs, gene therapy fragments) targeted fashion. In this paper, progress their recent years were summarized analyzed. was reviewed from perspective nanoparticle drug delivery systems, multi-responsive hydrogels. It expected that our work will help understand future development trends field.
Язык: Английский
Процитировано
46
Progress in Polymer Science, Год журнала: 2024, Номер 151, С. 101803 - 101803
Опубликована: Фев. 13, 2024
Язык: Английский
Процитировано
43
Journal of Translational Medicine, Год журнала: 2024, Номер 22(1)
Опубликована: Янв. 5, 2024
Abstract Acute lung injury (ALI) is a complex disease with numerous causes. This review begins discussion of development from direct or indirect pulmonary insults, as well varied pathogenesis. The heterogeneous nature ALI then elaborated upon, including its epidemiology, clinical manifestations, potential biomarkers, and genetic contributions. Although no medication currently approved for this devastating illness, supportive care pharmacological intervention treatment are summarized, followed by an assessment the pathophysiological gap between human animal models. Lastly, current research progress on advanced nanomedicines therapeutics in preclinical settings reviewed, demonstrating new opportunities towards developing effective ALI.
Язык: Английский
Процитировано
33
Journal of Nanobiotechnology, Год журнала: 2025, Номер 23(1)
Опубликована: Янв. 23, 2025
Язык: Английский
Процитировано
3
International Journal of Pharmaceutics, Год журнала: 2025, Номер 673, С. 125359 - 125359
Опубликована: Фев. 13, 2025
Язык: Английский
Процитировано
2
Acta Biomaterialia, Год журнала: 2022, Номер 148, С. 258 - 270
Опубликована: Июнь 18, 2022
Язык: Английский
Процитировано
66
Cell Biology International, Год журнала: 2022, Номер 46(9), С. 1320 - 1344
Опубликована: Июль 13, 2022
Abstract Immune‐mediated diseases (IMDs) are chronic conditions that have an immune‐mediated etiology. Clinically, these appear to be unrelated, but pathogenic pathways been shown connect them. While inflammation is a common occurrence in the body, it may either stimulate favorable immune response protect against harmful signals or cause illness by damaging cells and tissues. Nanomedicine has tremendous promise for regulating treating IMIDs. Various nanoparticles coated with nanotherapeutics recently fabricated effective targeted delivery inflammatory RNA interference (RNAi) offers genetic approach, particularly if traditional treatments ineffective IMDs. In cells, several signaling can suppressed using RNAi, which blocks expression of particular messenger RNAs. Using this molecular undesirable effects anti‐inflammatory medications reduced. Still, there many problems short‐interfering RNAs (siRNAs) treat IMDs, including poor localization siRNAs target tissues, unstable gene expression, quick removal from blood. Nanotherapeutics widely used designing siRNA‐based carriers because restricted therapy options review, we discussed recent trends fabrication siRNA nanodelivery systems, lipid‐based nanocarriers, liposomes, cationic lipids, stable nucleic acid‐lipid particles, polymeric‐based polyethylenimine (PEI)‐based nanosystems, chitosan‐based nanoformulations, inorganic material‐based hybrid‐based systems. We also introduced novel nanocarriers control IMIDs, such as pulmonary inflammation, psoriasis, bowel disease, ulcerative colitis, rheumatoid arthritis, etc. This study will pave way new avenues research into diagnosis treatment
Язык: Английский
Процитировано
44
ACS Nano, Год журнала: 2023, Номер 17(18), С. 17845 - 17857
Опубликована: Сен. 15, 2023
Brain inflammation is regarded as one of the leading causes that aggravates secondary brain injury and hinders prognosis ischemic stroke. After stroke, high quantities peripheral neutrophils are recruited to lesions release neutrophil extracellular traps (NETs), aggravation blood-brain barrier (BBB) damage, activation microglia, ultimate neuronal death. Herein, a smart multifunctional delivery system has been developed regulate immune disorders in brain. Briefly, Cl-amidine, an inhibitor peptidylarginine deiminase 4 (PAD4), encapsulated into self-assembled liposomal nanocarriers (C-Lipo/CA) modified by reactive oxygen species (ROS)-responsive polymers fibrin-binding peptide achieve targeting stimuli-responsive drug. In mouse model cerebral artery occlusion/reperfusion (MCAO), C-Lipo/CA can suppress NETs process (NETosis) further inhibit cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator interferon genes (cGAS-STING) pathway addition, MCAO mice treated with significantly mitigated reperfusion injury, reduction area infarction 12.1%, compared saline group about 46.7%. These results demonstrated C-Lipo/CA, which integrated microglia regulation, BBB protection, neuron survival, exerts potential therapy strategy maximize ameliorating mortality
Язык: Английский
Процитировано
42
ACS Applied Materials & Interfaces, Год журнала: 2023, Номер 15(22), С. 26298 - 26315
Опубликована: Май 26, 2023
Intestinal immune dysfunction and gut microbiota dysbiosis are critically causative factors in the pathogenesis of ulcerative colitis (UC); however, current first-line drugs for UC treatment clinics often remain great challenges due to their nontargeting therapeutic efficacy severe side effects. In study, colon-targeting nanoparticles based on Angelica sinensis polysaccharide with pH- redox-responsiveness were fabricated specifically release naturally active compound ginsenoside Rh2 colonic inflammatory site, which greatly alleviated symptoms improved microbial homeostasis. These dual responsive Rh2-loaded (Rh2/LA-UASP NPs) a particle size 117.00 ± 4.80 nm prepared using polymer LA-UASP obtained by grafting A. urocanic acid α-lipoic (α-LA). As expected, these Rh2/LA-UASP NPs achieved redox-responsive drug at pH 5.5 10 mM GSH. The stability, biocompatibility, vivo safety experiments exhibited had excellent ability significant accumulation colon. Meanwhile, could escape from lysosomes be efficiently internalized into intestinal mucosal cells, thereby effectively inhibiting proinflammatory cytokines. animal indicated that significantly integrity mucosa increased colon length compared mice. Additionally, weight loss, histological damage, inflammation level ameliorated. homeostasis flora short-chain fatty acids (SCFAs) after being treated Our study proved pH-and promising candidates treatment.
Язык: Английский
Процитировано
39
Advanced Functional Materials, Год журнала: 2023, Номер 33(30)
Опубликована: Апрель 26, 2023
Abstract Vascular restenosis after balloon dilation is largely caused by the over‐proliferation of smooth muscle cells, which triggered and exacerbated local excessive inflammation oxidative stress. The inflammatory stress cause tissue/cell damage, hamper endothelial functions, worsen intimal hyperplasia restenosis. A high level reactive oxygen species (ROS) overproduction regarded as main culprit. Therefore, efficiently inhibiting ROS over‐production or weightily depleting them great significance. Herein, a “ROS‐responsive/scavenging prodrug” introduced into coating for treatment vascular reversible phenylboronic ester‐bearing caffeic acid (CA) macromolecular prodrug (PBC) designed controlled on‐demand dual‐drug release level; released CA 4‐hydroxybenzyl alcohol exhibit efficient antioxidant anti‐inflammatory effects scavenging ROS, thereby regulating microenvironment protecting endothelium functions. To accelerate regeneration, pro‐endothelial microRNA‐126 further introduced. ROS‐responsive/scavenging prodrug/miRNA prevents hyperplasia, alleviates inflammation, improves healing in rat abdominal aorta model, may provide applicative perspectives next‐generation drug‐coated balloons other cardiovascular diseases treatment.
Язык: Английский
Процитировано
36